Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Queensland Health
Medtronic
Federal Trade Commission
Dow
Merck
Fish and Richardson
Citi

Generated: November 20, 2018

DrugPatentWatch Database Preview

Metoclopramide hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for metoclopramide hydrochloride and what is the scope of metoclopramide hydrochloride freedom to operate?

Metoclopramide hydrochloride is the generic ingredient in nine branded drugs marketed by Roxane, Emcure Pharms Ltd, Bedford, Fresenius Kabi Usa, Hospira, Lyphomed, Norbrook, Smith And Nephew, Teva Pharms Usa, West-ward Pharms Int, Actavis Mid Atlantic, Ani Pharms, Lannett Co Inc, Morton Grove, Paco, Pharm Assoc, Teva, Vistapharm, Wockhardt Bio Ag, Robins Ah, Novel Labs Inc, Salix Pharms, Meda Pharms, Quantum Pharmics, King Pharms, Clonmel, Halsey, Impax Labs Inc, Interpharm, Ipca Labs Ltd, Mutual Pharm, Northstar Hlthcare, Par Pharm, Par Pharm Inc, Sandoz, Schering, Sun Pharm Industries, Superpharm, Usl Pharma, Vintage Pharms, Watson Labs, and Yaopharma Co Ltd, and is included in sixty-four NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for metoclopramide hydrochloride. Forty-five suppliers are listed for this compound.

Pharmacology for metoclopramide hydrochloride
Medical Subject Heading (MeSH) Categories for metoclopramide hydrochloride
Synonyms for metoclopramide hydrochloride
(4-amino-5-chloro-2-methoxyphenyl)-N-[2-(diethylamino)ethyl]carboxamide, chlor ide
2542AH
364-62-5 (Parent)
4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide hydrochloride
4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide monohydrochloride
4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamidehydrochloride
4-Amino-5-Chloro-N-(2-(Diethylamino)Ethyl)-N-Anisamide
4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide hydrochloride
4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide hydrochloride
4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-benzamide hydrochloride
4-AMINO-5-CHLORO-N-[2-(DIETHYLAMINO)ETHYL]-2-METHOXYBENZAMIDE MONOHYDROCHLORIDE
4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide;hydrochloride
4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-o-anisamide hydrochloride
49625-23-2
7232-21-5
7B1QZY5SWZ
AB1009373
AC1L2MT3
AC1Q3LU2
AHR-3070-C
AK122291
AKOS015889947
AN-16617
AN-40630
API0003351
API0006827
AX8140039
Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy-, monohydrochloride
Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy-, monohydrochloride (9CI)
Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy-, monohydrochloride, monohydrate
Benzamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-, hydrochloride (1:1)
BG0253
C14H22ClN3O2.ClH
C14H22ClN3O2.HCl
CCG-212697
CCRIS 7142
Cerucal
CHEMBL1256771
CPD000058471
CTK8G1096
EINECS 230-634-5
EU-0100762
FT-0657870
FT-0672375
H780
HMS1568J19
HMS1920N15
HS-0006
I01-4517
J10269
KB-240082
KB-304048
KS-000018AM
LP00762
LS-175536
LS-20040
M 0763
Maxolon
MCULE-8548227068
METOCLOPRAMIDE HCL
Metoclopramide Hydrochloride (anhydrous)
Metoclopramide hydrochloride [USAN:JAN]
Metoclopramide hydrochloride anhydrous
Metoclopramide hydrochloride, solid
Metoclopramide Intensol
Metoclopramide monohydrochloride
Metoclopramide monohydrochloride monohydrate
Metozolv
Metozolv ODT
MFCD00058011
MFCD00150634
MLS000069667
MLS001074186
MLS002222202
MolPort-003-666-233
NC00519
NCGC00094102-01
NCGC00094102-02
NCGC00094102-03
NCGC00094102-04
NCGC00094102-05
NCGC00261447-01
NSC 354467
NSC-354467
NSC-757117
NSC354467
NSC757117
o-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-, monohydrochloride
o-Anisamide, monohydrochloride
Opera_ID_1671
OR068557
Paspertin
Pharmakon1600-01500410
Prestwick_332
Primperan (tablet)
Reglan ODT
Rimetin
S4289
SAM002554911
SBB058161
SCHEMBL205200
SMR000058471
SPECTRUM1500410
SR-01000000165
SR-01000000165-2
ST24028881
ST51015042
Tox21_500762
UNII-7B1QZY5SWZ
VU0239518-5
WLN: 2N2&2MVR DZ CG FO1 &GH

US Patents and Regulatory Information for metoclopramide hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms METOCLOPRAMIDE HYDROCHLORIDE metoclopramide hydrochloride SOLUTION;ORAL 071402-001 Jun 25, 1993 AA RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Morton Grove METOCLOPRAMIDE HYDROCHLORIDE metoclopramide hydrochloride SOLUTION;ORAL 070949-001 Mar 6, 1987 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Teva METOCLOPRAMIDE HYDROCHLORIDE metoclopramide hydrochloride TABLET;ORAL 072801-001 Jun 15, 1993 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bedford METOCLOPRAMIDE HYDROCHLORIDE metoclopramide hydrochloride INJECTABLE;INJECTION 072247-001 May 18, 1992 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Par Pharm METOCLOPRAMIDE HYDROCHLORIDE metoclopramide hydrochloride TABLET;ORAL 070342-001 Mar 25, 1986 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Actavis Mid Atlantic METOCLOPRAMIDE HYDROCHLORIDE metoclopramide hydrochloride SOLUTION;ORAL 071340-001 Aug 18, 1988 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sandoz METOCLOPRAMIDE HYDROCHLORIDE metoclopramide hydrochloride TABLET;ORAL 070850-001 Feb 3, 1987 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for metoclopramide hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
West-ward Pharms Int REGLAN metoclopramide hydrochloride INJECTABLE;INJECTION 017862-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Salix Pharms METOZOLV ODT metoclopramide hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 022246-002 Sep 4, 2009 ➤ Sign Up ➤ Sign Up
Meda Pharms REGLAN ODT metoclopramide hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021793-001 Jun 10, 2005 ➤ Sign Up ➤ Sign Up
Meda Pharms REGLAN ODT metoclopramide hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021793-002 Jun 10, 2005 ➤ Sign Up ➤ Sign Up
Meda Pharms REGLAN ODT metoclopramide hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021793-002 Jun 10, 2005 ➤ Sign Up ➤ Sign Up
Meda Pharms REGLAN ODT metoclopramide hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021793-001 Jun 10, 2005 ➤ Sign Up ➤ Sign Up
Salix Pharms METOZOLV ODT metoclopramide hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 022246-001 Sep 4, 2009 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Queensland Health
Medtronic
Federal Trade Commission
Dow
Merck
Fish and Richardson
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.